New Antibody 77A Enhances Immune Response Against Cancer

In a significant advancement in cancer treatment, researchers from The University of Texas MD Anderson Cancer Center have developed an investigational antibody therapy named 77A. This new therapy demonstrates potential in enhancing immune responses against various blood cancers, including myeloma and lymphoma, as well as solid tumors. The findings were presented on December 6, 2025, at the 67th American Society of Hematology (ASH) Annual Meeting.

Understanding the Mechanism of 77A

Led by Jun Wei, M.D., Ph.D., an assistant professor of Lymphoma & Myeloma, and principal investigator Robert Z. Orlowski, M.D., Ph.D., the study explores how 77A targets a protein known as HSP70. This heat shock protein is often overproduced in many tumors, allowing them to evade the immune system by fostering a suppressive tumor environment.

By targeting HSP70, the 77A antibody activates T cells and natural killer (NK) cells, crucial components of the immune system. In laboratory models, it not only enhanced the effectiveness of chemotherapy and radiation but also boosted the efficacy of immunotherapies across multiple tumor types. Notably, the antibody shows promise in improving immune cell responses against cancer, indicating a potential pathway to more effective immunotherapy treatments.

Next Steps and Future Implications

The encouraging results from laboratory tests highlight the ability of 77A to overcome treatment resistance that many patients experience with existing therapies. Early tests involving human immune cells indicate that 77A could enhance immune responses in healthy individuals, suggesting its versatility as a therapeutic option.

Orlowski stated, “These results give us confidence that 77A could become a versatile immunotherapy.” The research team plans to advance a humanized version of the antibody into clinical trials, aiming to evaluate its effectiveness in patients with various cancer types. With support from Blood Cancer United, formerly known as the Leukemia & Lymphoma Society, the development of 77A is set to progress, potentially offering new hope to patients facing challenging diagnoses.

The study represents a significant step forward in cancer research and immunotherapy, providing a foundation for future clinical applications of the 77A antibody. Further exploration into its capabilities will be crucial in determining its role in changing the landscape of cancer treatment.